Clinical features of pulmonary arterial hypertension in patients receiving dasatinib
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 90, Issue 11, Pages 1060-1064
Publisher
Wiley
Online
2015-08-19
DOI
10.1002/ajh.24174
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
- (2014) N. P. Shah et al. BLOOD
- Imatinib as Rescue Therapy in a Patient With Pulmonary Hypertension Associated With Gaucher Disease
- (2014) Nadine Al-Naamani et al. CHEST
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
- (2013) E. Jabbour et al. BLOOD
- Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension
- (2013) Marius M. Hoeper et al. CIRCULATION
- Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed
- (2013) C. Guignabert et al. EUROPEAN RESPIRATORY JOURNAL
- Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition
- (2013) Joanne A. Groeneveldt et al. EUROPEAN RESPIRATORY JOURNAL
- Updated Clinical Classification of Pulmonary Hypertension
- (2013) Gerald Simonneau et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Inflammation in Pulmonary Arterial Hypertension
- (2012) Laura C. Price et al. CHEST
- Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
- (2012) David Montani et al. CIRCULATION
- Pulmonary Arterial Hypertension Caused by Treatment with Dasatinib for Chronic Myeloid Leukemia -Critical Alert-
- (2012) Makoto Sano et al. INTERNAL MEDICINE
- Frequency of Pleural Effusions in Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Diseases
- (2011) Yi-feng Luo et al. CHEST
- Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia
- (2011) D. Dumitrescu et al. EUROPEAN RESPIRATORY JOURNAL
- Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia
- (2011) Ester M. Orlandi et al. LEUKEMIA RESEARCH
- Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
- (2011) Jan K Hennigs et al. BMC Pulmonary Medicine
- Drugs and toxins-associated pulmonary arterial hypertension: lessons learned and challenges ahead
- (2010) V. de Jesus Perez et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
- (2009) et al. EUROPEAN HEART JOURNAL
- ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
- (2009) Vallerie V. McLaughlin et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient
- (2008) D Mattei et al. BONE MARROW TRANSPLANTATION
- Doppler Myocardial Imaging for Early Detection of Right Ventricular Dysfunction in Patients With Pulmonary Hypertension
- (2008) Maytinee Kittipovanonth et al. JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
- Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia
- (2008) Walid Rasheed et al. LEUKEMIA RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search